Immortal Dragons backs 3D biofabrication to tackle organ failure
Immortal Dragons, a Singapore-based longevity fund, is increasing investment in 3D biofabrication and bio-inks to develop engineered, vascularized tissues aimed at addressing age-related organ failure while supporting clinical translation, regulatory engagement, and public advocacy across its 15+ portfolio companies.
Why it mattersSingapore-based fund's bet on 3D biofabrication using bio-inks implies investors should prioritize vascularized tissue startups.